Home | Business News | Browse by Publication | B | Biotech Business

MILLENNIUM/HARVARD MEDICAL SCHOOL SIGN CANCER RESEARCH PACT.

Article Excerpt
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Harvard Medical School's Office of Technology Development have announced an innovative collaboration agreement to pursue a research program in the area of protein homeostasis, an emerging and expanding field of cancer biology. Under the terms of the agreement, Harvard has granted Millennium a "Harvard Medical School's research initiatives in protein homeostasis, license to certain invention from the laboratory of Professor J. Wade Harper and the two institutions will jointly advance the program in this novel area of research over several years under a sponsored research agreement. Financial terms were not disclosed.

"Harvard Medical School's research initiatives in protein homeostasis, together with the demonstrated leadership of Millennium in this area, promises to advance our understanding of this important field and its role in regulating cancer cells," said Wade Harper, Ph.D., Bert and Natalie Vallee Professor of Molecular Pathology, Harvard Medical School. "We expect this collaboration to accelerate the important work the lab has accomplished to date."

Research has shown various pathways that regulate cellular protein homeostasis are linked to the pathologic properties of a broad range of cancers. The initial research-based agreement is focused on advancing knowledge in this...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!